Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TimoD implant in POAG
NCT06321562Phase 1Terminated
- Sponsor
- EyeD Pharma
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of timolol in primary open-angle glaucoma (POAG) (3 arms), sponsored by EyeD Pharma. Primary endpoints: Number and proportion of participants experiencing one or more serious adverse events at Week 108 and Number and proportion of participants experiencing one or more treatment-emergent adverse events at Week 108. Started Mar 2023; status: terminated.
02
Drugs
timolol
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT06321562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321562.